Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: Results of a phase 1 clinical trial

Clinical Cancer Research

Volumn 17, Issue 9, 2011, Pages 2987-2996

  Ribas, Antoni ^a   Weber, Jeffrey S ^c   Chmielowski, Bartosz ^a   Comin Anduix, Begonya ^a   Lu, David ^a   Douek, Michael ^a   Ragavendra, Nagesh ^a   Raman, Steve ^a   Seja, Elizabeth ^a   Rosario, Darlene ^b   Miles, Sabrina ^b   Diamond, David C ^b   Qiu, Zhiyong ^b   Obrocea, Mihail ^b   Bot, Adrian ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MannKind Corporation   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; MELAN A; MKC1106 MT VACCINE; MONOPHENOL MONOOXYGENASE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNIZATION; CELL EXPANSION; CHILL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HYPOALBUMINEMIA; HYPONATREMIA; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL MONITORING; LOW DRUG DOSE; MALE; MELANOMA; METASTASIS; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PLASMID; POLYADENYLATION; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; CANCER VACCINES; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; LYMPH NODES; MALE; MART-1 ANTIGEN; MELANOMA; MIDDLE AGED; MODELS, BIOLOGICAL; MONOPHENOL MONOOXYGENASE; NEOPLASM METASTASIS; SKIN NEOPLASMS; VACCINATION;

EID: 79955489170     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3272     Document Type: Article

References (33)

1. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001;411:1058-64. (Pubitemid 32612331)
2. Zinkernagel RM, Hengartner H. Regulation of the immune response by antigen. Science 2001;293:251-3. (Pubitemid 32694732)
3. Smith KA, Meisenburg BL, Tam VL, Pagarigan RR, Wong R, Joea DK, et al. Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus- transformed tumors. Clin Cancer Res 2009;15:6167-76.
4. Wong RM, Smith KA, Tam VL, Pagarigan RR, Meisenburg BL, Quach AM, et al. TLR-9 signaling and TCR stimulation co-regulate CD8(+) T cell-associated PD-1 expression. Immunol Lett 2009;127:60-7.
5. Smith KA, Qiu Z, Wong R, Tam VL, Tam BL, Joea DK, et al. Multivalent immunity targeting tumor-associated antigens by intra-lymph node DNA-prime, peptide-boost vaccination. Cancer Gene Ther 2011;18:63-76. doi:10.1038/cgt.2010. 45.
6. Smith KA, Tam VL, Wong RM, Pagarigan RR, Meisenburg BL, Joea DK, et al. Enhancing DNA vaccination by sequential injection of lymph nodes with plasmid vectors and peptides. Vaccine 2009; 27:2603-15.
7. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Pérarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 1997;185:2043-51. (Pubitemid 27265987)
8. Cerottini JC, von Fliedner V, Boon T. Recognition of tumor-associated antigens by T lymphocytes: from basic concepts to new approaches. Oncology 1992;3:11-6.
9. Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002;188:51-64. (Pubitemid 35398865)
10. Lesimple T, Neidhard EM, Vignard V, Lefeuvre C, Adamski H, Labarrìere N, et al. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intra-nodal routes in metastatic melanoma patients. Clin Cancer Res 2006;12: 7380-8.
11. Tagawa ST, Lee P, Snively J, Boswell W, Ounpraseuth S, Lee S, et al. Phase 1 study of intra-nodal delivery of a plasmid DNA vaccine for patients with stage IV melanoma. Cancer 2003;98:144-54. (Pubitemid 36741137)
12. Weber J, Boswell W, Smith J, Hersh E, Snively J, Diaz M, et al. Phase 1 trial of intra-nodal injection of a Melan A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J Immunother 2008;31: 215-23.
13. Sato Y, Roman M, Tighe H, Lee D, Corr M, Nguyen MD, et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996;273:352-4. (Pubitemid 26250262)
14. Klinman DM, Ishii KJ, Verthelyi D. CpG DNA augments the immunogenicity of plasmid DNA vaccines. Curr Top Microbiol Immunol 2000;247:131-42.
15. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180:347-52. (Pubitemid 24181083)
16. Brichard V, Van Pel A, W€olfel T, W€olfel C, De Plaen E, Lethé B, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178: 489-95. (Pubitemid 23218197)
17. Micheletti F, Bazzaro M, Canella A, Marastoni M, Traniello S, Gavioli R, et al. The lifespan of major histocompatibility complex class I/peptide complexes determines the efficiency of cytotoxic T-lymphocyte responses. Immunology 1999;96:411-5. (Pubitemid 29118329)
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
19. Ribas A, Camacho LH, Lee SM, Hersh EM, Brown CK, Richards JM, et al. Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. J Trans Med 2010;8:89. doi:10.1186/1479-5876-8-89.
20. Ribas A, Comin-Anduix B, Economou JS, Donahue TR, de la Rocha P, Morris LF, et al. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res 2009;15:390-9.
21. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008;26:527-34. (Pubitemid 351264344)
22. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009;21: 233-40.
23. Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 2007;4:e176.
24. Ferguson AR, Engelhard VH. CD8 T cells activated in distinct lymphoid organs differentially express adhesion proteins and coexpress multiple chemokine receptors. J Immunol 2010;184:4079-86.
25. Bogunovic D, O'Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, Adams S, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A 2009;106:20429-34.
26. Goff SL, Smith FO, Klapper JA, Sherry R, Wunderlich JR, Steinberg SM, et al. Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J Immunother 2010;33:840-7.
27. Huang J, Kerstann KW, Ahmadzadeh M, Li YF, El-Gamil M, Rosenberg SA, et al. Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy. J Immunol. 2006;176:7726-35. (Pubitemid 43849073)
28. Lin Y, Gallardo HF, Ku GY, Li H, Manukian G, Rasalan TS, et al. Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy 2009;11:1-11.
29. Lizée G, Radvanyi LG, Overwijk WW, Hwu P. Immunosuppression in melanoma immunotherapy: potential opportunities for intervention. Clin Cancer Res 2006;12:2359s-65s.
30. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008;371:771-83.
31. Ribas A, Glaspy JA, Lee Y, Dissette VB, Seja E, Vu HT, et al. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother 2004;27:354-67. (Pubitemid 39121924)
32. Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, Camacho LH, et al. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med 2008;6:22.
33. Kwong GA, Radu CG, Hwang K, Shu CJ, Ma C, Koya RC, et al. Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells. J Am Chem Soc 2009;131:9695-703.